Tue, Sep 2, 2014, 12:33 AM EDT - U.S. Markets open in 8 hrs 57 mins

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan Oct 25, 2013 10:08 AM Flag

    S&P analyst positive about partnering VX 509 based on clinical trial data

    October 21, 2013
    09:42 am ET ... S&P CAPITAL IQ KEEPS BUY OPINION ON SHARES OF VERTEX
    PHARMACEUTICALS (VRTX 77.06****):We keep our $104 NPV-based target
    price. VRTX reports positive Phase IIb data for pipeline candidate JAK3 inhibitor
    VX-509 in rheumatoid arthritis.We see efficacy as promising, with statistically
    significant response improvements over placebo. Despite a higher adverse event
    rate over placebo, there were fewer discontinuations, and we think its safety is
    consistent with peers.We expect VRTX to out-license VX-509 for late-stage study
    and, despite an outlook for a competitive market, we view the rheumatoid arthritis
    market as lucrative and likely to attract partnering interest. /S.Silver

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Partnering will bring max 800 million in the best case senerio ( look at RIGL/ANZ or INCY/LLY deal). This is nothing and this could be an earning from this drug in 6 months. VRTX should have sufficient cash ( 150 M) to fund phase III for VX 509 over next 2 years and once data is mature they should look for distribution partner in Europe and rest of the World. This could become the largest franchise for VRTX in future due to growth and expanding indications. CF market lacks growth and prices of drugs will go down with more competition in this field. What Hepatitis C partnering with JNJ has given to VRTX? Big fish has only one respect for small fish, their tummy. GILD has survived because it never partner any big product except Tamiflu during their growth phase.

      • 1 Reply to rojospan
      • They have already stated that they will partner for 509 (and flu). Nothing has developed over 18 months on either. They seem to be stuck in neutral on this strategy. Exiting HCV is probably a good thing at this point, the kool aid has turned sour on that. Big miss. I have to say, while I am holding for now and have been long for a couple of years, I am losing faith in their ability to execute on business strategy. The good science is being held back by executive incompetence. I expect the stock to bump up a little on Tuesdays call. Massive cuts bring expenses under control. Longer term, they better have more than CF. They have a lot of cash and should use it.

 
VRTX
93.57+0.77(+0.83%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exelixis, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Criteo SA
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT